Novel Biomarker Serum Calprotectin for Early Diagnosis of Diabetic Peripheral Neuropathy in Type 2 Diabetes Patients

Document Type : Original Article

Authors

Abstract

Background: Calprotectin was identified as an endogenous activator of Toll-like receptor 4 (TLR4) and as receptor for advanced glycation end product (RAGE). Elevated plasma levels of calprotectin have been reported in a variety of chronic inflammatory conditions. Elevated calprotectin levels have been reported to predict microvascular alterations in type 2 diabetes (T2DM) patients.
Objective: To make an up to date review of serum level of calprotectin as a predictor for early diagnosis of peripheral neuropathy in type 2 diabetes patients.
Patients and methods: A total number of 90 subjects were included in the study after fulfillment of the inclusion and exclusion criteria. Calprotectin was measured for all the 90 subjects.
Results: Serum calprotectin levels were significantly higher in group III “diabetics with neuropathy” compared to group II “diabetics without neuropathy “and group I “healthy controls”.
Conclusion: High levels of calprotectin were detected in type 2 diabetic patients with peripheral neuropathy.

Keywords

The Egyptian Journal of Hospital Medicine
Volume 82, Issue 2
January 2021
Pages 379-385

Files

Share

How to cite

Statistics